---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-25-000157"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2025-07-30T23:59:59+00:00"
generated_at: "2026-05-17T23:26:40.618697+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neurocrine Biosciences Q2 2025: Revenue $687.5M up 16.5% YoY; valbenazine Phase 3 schizophrenia miss

## Summary
- Total revenue $687.5M; INGREZZA $624.4M (+8% YoY), CRENESSITY $53.2M (launch year).
- GAAP diluted EPS $1.06 (vs $0.63 Q2 2024); Non-GAAP diluted EPS $1.65 (vs $1.63).
- INGREZZA 2025 net product sales guidance narrowed to $2.50-2.55B from $2.50-2.60B.
- CRENESSITY: 664 new patient enrollment start forms in Q2; 76% reimbursement coverage for dispensed scripts.
- Phase 3 study of valbenazine for adjunctive schizophrenia did not meet primary endpoint; safety consistent.

## SEC filing metadata
- accession: 0000914475-25-000157
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2025-07-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447525000157/0000914475-25-000157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447525000157/nbix-20250730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-25-000157
- JSON: https://secwatch.observer/filing/0000914475-25-000157.json
- Plain text: https://secwatch.observer/filing/0000914475-25-000157.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.